In the new CEO's first earnings conference call in May, SCMP CEO Peter Greenleaf outlined the 3 important elements of great biopharmaceutical companies: Great people/partnerships, great science and strong fundamentals. I agree with his observations and will add more color to these three aspects of Sucampo. Thereafter, I will dive into the details of Amitza, the main value driver of Sucampo's sales and present the future outlook of Sucampo to evaluate its upside potential in the next year.
People and partnerships
As of Q1 2014, Sucampo had 77 full-time employees, ~30% with doctoral or other advanced degrees. who are engaged in research and development. The R&D costs have held steady for the past 2 years with an annual run rate...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|